Petition to Delay Biosimilar Game in U.S. Picks up Steam

While other countries are building a strong lineup of biosimilars, the U.S. entry into the game could be delayed until 2022  if Abbott Laboratories succeeds in making its case that allowing a biosimilar of a reference drug approved before March 23, 2010, would be an illegal government taking of private property.